Page URL: https://www.bionews.org.uk/page_94988

Personalised cancer vaccines show promise

13 April 2015
Appeared in BioNews 797

A new type of cancer vaccine that enriches the immune system with tailor-made anti-tumour cells has shown early signs of promise.

The small-scale trial was conducted at the Washington University School of Medicine in St Louis, USA and published in the journal Science. Three patients with advanced melanoma - a type of skin cancer - received the experimental treatment almost two years ago. Since then, one has been in remission, the second remained stable throughout the treatment and the third showed a temporary improvement.

Melanoma is caused by the sun's ultraviolet radiation damaging the DNA of skin cells, leading to mutations that vary from person to person. Some of these mutations result in small unique proteins, or neoantigens, that end up on the surface of tumour cells. These can be ideal targets for bespoke anti-cancer vaccines.

The researchers sequenced the complete genome of each patient, and they then compared the DNA of the tumour cells with the DNA in that person's healthy tissues. This process helped them identify every possible unique neoantigen for each patient. They narrowed down the search using a computer algorithm to determine the best candidates for developing a vaccine. To increase the chances of success, seven neoantigens were selected for each patient.

The neoantigens were mixed with specialised immune cells, known as dendritic cells, from each patient. When these cells were re-introduced into the patients' blood stream, they instructed their immune T cells to find and attack the tumour cells that bore the selected neoantigens.

Dr Gerald Linette, who led the trial, said: 'Many researchers have hypothesised that it would be possible to use neoantigens to broadly activate the human immune system, but we didn't know that for sure until now.'

A series of blood tests from the patients showed that in each case they had produced a substantial immune response against their individual melanomas. Dr Linette noted: 'Our team is very encouraged by the quality of the immune response directed against the melanoma neoantigens in all three patients. Our results are preliminary, but we think the vaccines have therapeutic potential.'

However, the team acknowledges that it's too early to judge the effectiveness of the treatment. The melanoma participants had received surgery and chemotherapy prior to the tailored vaccination. Further trials with more patients will follow later this year.

Dr Alan Worsley, of Cancer Research UK, said: 'At the moment it's not clear how effective this immunotherapy would be at killing cancer cells in the body and improving survival, but this promising study sets the stage for creating vaccines that are designed to target each patient's individual tumour in the future.'

Personalised vaccines might also be developed against other types of cancer with high mutation rates, including lung, bladder and certain colorectal, breast and ovarian cancers.

SOURCES & REFERENCES
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
19 February 2018 - by Charlott Repschlager 
Researchers successfully used inactivated induced pluripotent stem cells to elicit an immune response against different cancers in mice...
10 July 2017 - by Meetal Solanki 
A revolutionary vaccine uses the patient’s own immune response to target tumour cells and could be the first step in bespoke, precision medicine. 
12 December 2016 - by Ayala Ochert and Ebtehal Moussa 
Researchers have successfully treated a woman with colon cancer using her own immune cells to target a cancer-causing gene that had previously been considered 'undruggable'...
22 February 2016 - by Julianna Photopoulos 
Trials using genetically engineered immune cells have shown 'extraordinary results' in treating blood cancers in terminally ill patients, say researchers...
15 February 2016 - by Dr James Heather 
The prolific and popular 'Stuff You Should Know' podcast takes us down the pub to talk personalised medicine...
2 November 2015 - by Arit Udoh 
The US Food and Drug Administration has approved a drug derived from a genetically modified herpes virus for the treatment of melanoma that cannot be removed by surgery...
28 September 2015 - by Kirsty Oswald 
NHS England's national medical director, Sir Bruce Keogh, has outlined how the organisation's approach to personalised medicine will develop over the coming years and expand beyond the work of the 100,000 Genomes Project...
14 September 2015 - by Dr Julia Hill 
The 2015 Lasker Awards are being given to three scientists who made ground-breaking discoveries in cancer and genetics, and to the organisation Doctors without Borders for its work on the Ebola crisis....
15 June 2015 - by Hannah Somers 
Two US studies have identified specific genetic mutations in gliomas which correlate with how the tumours will behave and respond to treatment...
20 April 2015 - by Dr Lucy Freem 
Genetic testing to guide the choice of cancer treatment may be misleading unless tumour DNA is compared to normal DNA...
22 September 2014 - by Dr Lanay Griessner 
A skin cancer drug designed to be effective in patients whose cancer is driven by a specific gene mutation has been recommended by the National Institute for Health and Care Excellence to treat patients with advanced melanoma...
22 April 2013 - by Siobhan Chan 
Scientists have identified an eight-gene 'signature' that can predict patients' response to chemotherapy...
5 November 2012 - by Maria Sheppard 
A drug which prolongs life in a form of skin cancer associated with a genetic mutation has been recommended for use on the NHS...
11 June 2012 - by Dr Tamara Hirsch 
Two drugs targeting advanced melanoma linked to a mutation in the BRAF gene are more effective than current chemotherapy at slowing the progress of the skin cancer, clinical trial results indicate...
12 October 2009 - by Dr Will Fletcher 
Stem cells could potentially be used to vaccinate people against colon cancer. This surprising conclusion was made by researchers from China and the US after laboratory mice immunised with human embryonic stem (ES) cells experienced a dramatic decline in tumour growth compared to control mice. The idea that embryonic material may generate an anti-tumour response is an old one, but one that has never been tested outside animal research, so to find such an effect wit...
25 October 1999 - by BioNews 
Johns Hopkins researchers have reported the first successful use of gene therapy to activate the human immune system against prostate cancer. The results are published in the October 15 issue of Cancer Research. The Johns Hopkins gene therapy for prostate cancer is tailor-made for patients. The vaccine activates the immune...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.